Company: VRCA
Filing Date: 2025-03-11
Form Type: S-3
Source: 0001193125-25-052031
Chunk: 13

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: S-3
Chunk 13
---
| • |     | our estimates regarding future revenue, expenses and needs for additional financing; |

| • |     | our ability to continue as a going concern; |

| • |     | our expectations regarding the commercialization of YCANTH (VP-102) for                                          
 the treatment of molluscum contagiosum as well as our plans to develop and commercialize our product candidates; |

| • |     | the timing of our planned clinical trials for our product candidates; |

| • |     | our ability to maintain regulatory approvals for YCANTH (VP-102) for the                                                                                          
 treatment of molluscum contagiosum or obtain approval for YCANTH (VP-102) for the treatment of common warts and VP-315 for the treatment of basal cell carcinoma; |

| • |     | the clinical utility of our product candidates; |

| • |     | our commercialization, marketing and manufacturing capabilities and strategy; |

| • |     | our expectations about the willingness of healthcare professionals to use YCANTH       
 (VP-102) for the treatment of molluscum contagiosum and any of our product candidates; |

| • |     | our expectations about third-party payors to reimburse or patients to pay for YCANTH (VP-102) for the treatment of molluscum contagiosum and any of our product candidates; |

| • |     | our intellectual property position; |

| • |     | our plans to in-license, acquire, develop and commercialize additional 
 product candidates for other dermatological conditions;                |

| • |     | our competitive position and the development of and projections relating to our competitors or our industry; |

| • |     | our ability to identify, recruit and retain key personnel; |

| • |     | the impact of laws and regulations; |

| • |     | our ability to maintain compliance with the continued listing standards of the Nasdaq Global Market and |

| • |     | our estimates regarding future revenue, expenses and needs for additional financing. |

We caution you that the foregoing list may not contain all of the forward-looking statements made in this prospectus. In some cases, you can identify forward-looking statements by the words “may,” “might,” “can,” “will,” “to be,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” 7

“predict,”